Something significant happened in Washington on September 1, 2026. Congresswoman Nancy Mace introduced the PEPTIDES for Veterans Act, legislation that would direct the Department of Veterans Affairs to formally study peptide-based therapies and their potential applications for veterans. The bill doesn't declare peptides proven. It doesn't approve experimental treatments. And it doesn't immediately give veterans access to peptide therapy. What it does is arguably more interesting: It asks the VA to investigate the subject directly. That could represent an important shift in how experimental peptide therapies are discussed at the federal level. For years, peptide discussions have largely lived in the worlds of research, bodybuilding, biohacking, longevity and online wellness communities. Now the conversation has reached Congress. What Is the PEPTIDES for Veterans Act? The legislation is officially called the Providing Evidence-based Peptide Therapies to Improve Delivery and Expanded Services for Veterans Act, or the PEPTIDES for Veterans Act. It was introduced in the House on September 1, 2026, by Representative Nancy Mace of South Carolina as H.R. 10212. The bill has been referred to the House Committee on Veterans' Affairs. Its central objective is straightforward: Direct the VA to investigate the potential benefits, safety and therapeutic applications of peptide-based therapies for veterans receiving VA care. That's an important distinction. The legislation isn't saying: "Peptides work." It's effectively saying: "There is enough interest in this area to justify formally studying the evidence." That is a very different claim. And scientifically, it's the more responsible one. What Would the VA Actually Have to Do? Under the proposed legislation, the VA would first conduct a comprehensive review of existing regulations and guidance surrounding peptide therapies. The bill then calls for an 18-month study examining peptide-based therapies across several potential areas, including: